Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Andrew L, Pecora"'
Autor:
Eric Hansen, Roman A Tuma, David S. Siegel, Aaron A Stein, Noa Biran, Valerie R.C. Allusson, Eric J Costanzo, Michael Marafelias, Lauren S Koniaris, Ronaldo C. Go, Vincent Vivona, George S Lin, Lisa Tank, Micky Simwenyi, Jaeil Ahn, Andre Goy, Andrew L. Pecora, Ihor S. Sawczuk, Joseph Reichman, William F Oser, Kim L Carpenter, Shivam Mathura, Louis Brusco, Urszula Bednarz, Stuart L. Goldberg, Brittany A Sinclaire, Shuqi Wang, Andrew Ip, Daniel W Varga
Publikováno v:
The Lancet Rheumatology
Summary Background Tocilizumab, a monoclonal antibody directed against the interleukin-6 receptor, has been proposed to mitigate the cytokine storm syndrome associated with severe COVID-19. We aimed to investigate the association between tocilizumab
Autor:
Alan P Skarbnik, Paul Fields, Pashna N. Munshi, Michele L. Donato, Scott D. Rowley, Joshua Zenreich, Tatyana Feldman, Andrew L. Pecora, David H. Vesole, Lori A. Leslie, Dante B. Descalzi-Montoya, Andre Goy, Noa Biran, Themba Nyirenda, Rena Feinman, Robert Korngold
Publikováno v:
Transplantation and cellular therapy. 27(5)
Autologous hematopoietic stem cell transplantation (ASCT) is a standard-of-care treatment for many hematologic malignancies. Progression of disease after ASCT is the primary cause of treatment failure. In this Phase Ib trial, we studied the safety an
Autor:
Eric Hansen, Samuel La Capra, Ihor S. Sawczuk, Greggory E. Mojares, Michael Marafelias, Arthur Calise, Brittany A Sinclaire, Bradley L. Pulver, Andrew L. Pecora, Joseph P. Underwood, Andrew Ip, Frank J. Cunningham, Jaeil Ahn, Marie G. Ponce, Robert L. Sweeney, Dominic Ruocco, David M Walker, Rajiv Prasad, Yizhao Zhou, Paul Mastrokyriakos, Stuart L. Goldberg, Kristy L. Ziontz, Michael P. Eagan, Urszula Bednarz, Andre Goy
Publikováno v:
BMC Infectious Diseases, Vol 21, Iss 1, Pp 1-12 (2021)
BMC Infectious Diseases
BMC Infectious Diseases
BackgroundHydroxychloroquine has not been associated with improved survival among hospitalized COVID-19 patients in the majority of observational studies and similarly was not identified as an effective prophylaxis following exposure in a prospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d441f1d43e8919063ba30fa9b357ee15
https://doi.org/10.1101/2020.08.20.20178772
https://doi.org/10.1101/2020.08.20.20178772
Autor:
Kathyrn Tanenbaum, William Kea, Andre Goy, Denis Fitzgerald, May D. Abdo-Matkiwsky, Usha Niranjan, Julianne Wilkins Childs, Sukhi Kaur, Eric V Schultz, Dhakshila Paramanathan, Kelly Choi, Stuart L. Goldberg, James W. Lee, Samira Daswani, Andrew L. Pecora, Matthew Axelrod
Publikováno v:
Journal of Clinical Oncology. 34:10065-10065
10065Background: Cancer patients (pts) are more than twice as likely to enter bankruptcy as the general US population. It is unknown how often pts with metastatic cancer are concerned about the fin...
Autor:
Stuart L. Goldberg, Amy Guo, Mitra Corral, Nikita Mody-Patel, Andrew L. Pecora, Er Chen, Marianne Laouri
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(17)
Purpose To determine the incidence and complications of myelodysplastic syndromes (MDS) among Medicare beneficiaries. Methods Retrospective review of 2003 Medicare Standard Analytic Files utilizing International Classification of Diseases for Oncolog
Autor:
Anthony R. Mato, Michele L. Donato, Christina Howlett, Scott D. Rowley, Tania Zielonka, Pritish M Bhattacharyya, Raihan Faroqui, Maria Rosario, Andrew L. Pecora, David H. Vesole, Tatyana Feldman, Andre Goy, Mary Timberg, Kar Fai Chow, Gabriella Gadaleta
Publikováno v:
Blood. 122:2141-2141
Introduction There is a growing awareness of the molecular heterogeneity of DLBCL beyond the GC and non-GC well established subtypes. “Double-hit” lymphoma (DHL) harboring rearrangements of c-Myc and BCL2 have been clearly associated with a poor
Autor:
Doron Lipson, Anthony R. Mato, Tania Zielonka, Kai Wang, Kar Fai Chow, Andre Goy, Michelle Nahas, Jie He, Roman Yelensky, Vincent A. Miller, Pritish K. Bhattacharyya, Geoff Otto, Amy Donahue, Phil Stephens, Ewelina Protomastro, Jeffrey S. Ross, Andrew L. Pecora, Tatyana Feldman
Publikováno v:
Blood. 122:501-501
Background The implementation of chemoimmunotherapy (R-CHOP) has dramatically improved the outcome of B-cell NHL particularly DLBCL (> 50% OS at 5 years with very few late relapses). Most failures to R-CHOP occur early (80% in the 1st 18 months), are
Autor:
Marisa Valentinetti, Anthony R. Mato, Carolanne Carini, Judith Smith, Andre Goy, Joshua R. Richter, Michele L. Donato, Stuart L. Goldberg, David S. Siegel, Ewelina Protomastro, Susan Stives, Andrew L. Pecora, Tatyana Feldman, Gabriella Gadaleta, Coleen Bejot, Mary Timberg, David H. Vesole, Scott D. Rowley
Publikováno v:
Blood. 120:3710-3710
Abstract 3710 Background: Relapsed/refractory DLBCL has poor prognosis in the rituximab era. Pts who failed Rituximab-containing initial chemo regimen within 12 mo do particularly poorly. (ORR 46–51% vs. 83–88%, EFS 20% vs. 45% at three years). N
Autor:
Mary Timberg, Tania Zielonka, Tatyana Feldman, Michele L. Donato, Susan Stives, Ewelina Protomastro, Gabriella Gadaleta, Andrew L. Pecora, Coleen Bejot, Pritish K. Bhattacharyya, Anthony R. Mato, Scott D. Rowley, Andre Goy
Publikováno v:
Blood. 120:3658-3658
Abstract 3658 Background: While current front-line treatment options for the management of MCL are still debated, a growing consensus in the lymphoma community suggest that MCL pts show superior outcomes with either consolidative ASCT or dose-intensi
Autor:
Rebecca Elstrom, Katherine Facchin, Andre Goy, Morton Coleman, Gabriella Gadaleta, Tatyana Feldman, Anthony R. Mato, Coleen Bejot, Scott D. Rowley, Jia Ruan, Michele L. Donato, Usama Gergis, Tsiporah B. Shore, Andrew L. Pecora, Kathryn Waksmundzki, Richard R. Furman, Ewelina Protomastro, John P. Leonard, Tania Zielonka
Publikováno v:
Blood. 120:4269-4269
Abstract 4269 Introduction: High-dose chemotherapy with autologous stem cell rescue (HDT-ASCT) remains the standard of care for patients with chemosensitive, relapsed diffuse large B-cell lymphoma (DLBCL). Because of concern for unacceptable toxicity